Abstract:Our previous study has found this new BT technique could not only improve the target dose coverage, but also maintain the organ at risk (OARs) to a reasonable lower dose for advanced cervical cancer patients. The aim of this study is to explore potentially prognostic factors for survival and toxicity for the first time in the world. Sixty-three cervical cancer patients (FIGO stage IIB-IVA) who received ICBT+IMRT were retrospectively analyzed. They all received concomitent chemoradiotherapy. External body radiotherapy was performed with IMRT. A total dose of 45-50Gy was applied in 25 fractions for 5 weeks. The patients underwent 4 fractions BT at 6-6.5Gy/fraction twice a week. The targets and OARs were contoured by the professional physicians according to the GEC ESTRO recommendations. The complementary IMRT plan was delivered immediately after HDR-ICBT, with the applicator in position. D90, D100, V100, Vpd, V2xpd, volumes of target and D0.1cc, D1cc, D2cc, DICRU of OARs were recorded. CTCAE was used to evaluate the acute and late toxicities. The log-rank test and Cox regression mode were used for univariate and multivariate survival prognostic analyses. Logistic regression analysis was used for the toxic prognostic analyses. The 2-year local control rate (LC), distant metastasis free rate and overall survival rate were 94.8%, 84.9% and 91.6%. Both acute and late incidence of proctitis, rectal hemorrhage, small intestine obstruction and cystitis were low, the grade was not exceed G4 (Table 1.). None rectum and bladder perforation has occurred. The mean D90 of GTV, HR-CTV and IR-CTV were 93.3±4.3Gy, 81.8±2.5Gy, and 72.8±1.1Gy, and the mean D2cc of bladder, rectum, sigmoid and small intestine were lower than 75Gy. For BT dose, the mean D100 of GTV, HR-CTV and IR-CTV were 32.1±2.6, 23.2±2.2 and 14.7±1.3Gy, the mean V100 of HR-CTV and IR-CTV were 92.9%±1.2%, 92.7%±1.3%, and the mean DICRU of rectum and bladder were 22.3±4.6Gy and 18.3±3.3Gy. The D100 of IR-CTV was a prognostic factor for LC in univariate analyses among these factors (p = 0.041), but it had no statistical significance in multivariate analysis. The DICRU of bladder was a prognostic factor for the late cystitis (p = 0.045). This promising new technique could achieve the relatively higher local control rate and lower acute and late toxicity incidence. D100 of IR-CTV might be considered as a new potentially prognostic indicator for LC. DICRU of bladder still remained a prognostic factor for late cystitis, and it might have a more important role than D2cc.Scientific Abstract 2697; TableIncidence and grade of acute and late toxicityToxicityG1-2(%)G3(%)G4-5(%)Acute proctitis30.200Acute rectal hemorrhage1.600Acute small intestinal obstruction1.600Acute cystitis15.91.60Late proctitis3.200Late small intestinal obstruction1.61.60Late cystitis4.81.60Late rectal hemorrhage000 Open table in a new tab

Factors affecting D90 High-risk Clinical Target Volumes (HR-CTV dose) of intracavitary and interstitial brachytherapy in locally advanced cervical cancer

Comparison of Computed Tomography- and Magnetic Resonance Imaging-Based Target Delineation for Cervical Cancer Brachytherapy

Comparison of Computed Tomography and Magnetic Resonance Imaging in Cervical Cancer Brachytherapy: A Systematic Review.

Prognostic Factors For Toxicity And Survival In Advanced Cervical Cancer Patients Treated With High-Dose-Rate (Hdr)-Intracavitary Brachytherapy (Icbt) Combined With Complementary Intensity Modulated Radiation Therapy (Imrt)

Prognostic factors for IB2-IIIB cervical cancer patients treated by radiation therapy with high-dose-rate brachytherapy in a single-institution study

The prognostic effect of tumor volume, reduction ratio, and cumulative doses on external beam radiotherapy with central-shielding method and image-guided adaptive brachytherapy for cervical cancer

High-dose-rate brachytherapy in uterine cervix carcinoma: a comparison of dosimetry and clinical outcomes among three fractionation schedules

Image guided radiation therapy boost in combination with high-dose-rate intracavitary brachytherapy for the treatment of cervical cancer

Clinical outcomes of adaptive intracavitary and interstitial brachytherapy technique in locally advanced cervical cancer: A real-world data

Four-Dimensional Image-Guided Adaptive Brachytherapy for Cervical Cancer: A Systematic Review and Meta-Regression Analysis

Intra-fractional dosimetric analysis of image-guided intracavitary brachytherapy of cervical cancer

Dosimetric Study for Cervix Carcinoma Treatment Using Intensity Modulated Radiation Therapy (IMRT) Compensation Based on 3D Intracavitary Brachytherapy Technique

3d Hdr Intracavitary Brachytherapy Combined With Complementary Applicator-Guided External Beam Radiotherapy For 338 Patients With Stage Iib-Iiib Uterine Cervical Cancer: A Single-Center Phase Ii Prospective Study With Long-Term Follow-Up.

Three Dimensional Printed Individual Template Based (192)ir High-Dose Rate Interstitial Brachytherapy for Central Recurrent Gynecologic Cancer: A Phase II Clinical Trial

Clinical and dosimetric correlation in terms of treatment response, bladder and rectal toxicities in cervical cancer patients treated with cobalt 60 high dose rate brachytherapy

Preliminary Clinical Outcomes and Dosimetry Study on Adaptive Imrt Integrated Hdr Brachytherapy in Local Advanced Uterine Cervical Cancer.

Efficacy and safety of 3-dimensional printing noncoplanar template (3D-PNCT)-assisted high-dose-rate interstitial brachytherapy (HDR-ISBT) for reirradiation of recurrent cervical cancer: a prospective cohort

Clinical efficacy of MRI image-based three-dimensional brachytherapy in locally advanced cervical cancer

[Effect of Brachytherapy Source Dwell Position on Dose Distribution in Cervical Cancer Therapy]

The Preliminary Results of 3-Dimensional Printed Individual Template Assisted 192ir High-Dose Rate Interstitial Brachytherapy for Central Recurrent Gynecologic Cancer

Dosimetric parameters and safety analysis of 3D-printing non-coplanar template-assisted interstitial brachytherapy for non-centrally recurrent cervical cancer